ArticleJournal of cellular and molecular medicine2026
RNA Metabolism Genes as Prognostic Biomarkers and Therapeutic Targets in Colorectal Cancer Based on the Analysis of Single-Cell and Bulk-RNA Sequencing Data.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Colorectal cancer (CRC) is one of the most common malignancies worldwide and remains a major cause of cancer-related mortality. Increasing evidence suggests that aberrant RNA metabolism contributes to tumour initiation, progression and therapeutic resistance. In this study, we integrated single-cell RNA sequencing and bulk transcriptomic data to identify RNA metabolism-related genes (RMRGs) associated with CRC progression and evaluate their clinical significance. Through comprehensive bioinformatics analyses, 39 differentially expressed RMRGs were identified, with high RMRG activity predominantly enriched in epithelial cell populations. Cell-cell communication analysis revealed enhanced interactions between epithelial cells and other cell types within the tumour microenvironment. Further integration of single-cell and bulk RNA-sequencing datasets identified PCBP3 and NGRN as key prognostic genes. A two-gene prognostic model based on PCBP3 and NGRN was established and validated in independent cohorts, demonstrating favourable predictive performance. Human Protein Atlas data further confirmed the expression of both proteins in colorectal cancer tissues. Immune infiltration analyses indicated that PCBP3 and NGRN were associated with distinct immune-cell infiltration patterns and immunotherapy-related immune status. Functional experiments demonstrated that silencing PCBP3 or NGRN significantly inhibited the proliferation and invasion of HCT116 colorectal cancer cells. Moreover, Western blot analysis suggested that these effects may be mediated, at least in part, through regulation of the PI3K/AKT signalling pathway. Collectively, our findings identify PCBP3 and NGRN as promising prognostic biomarkers and potential therapeutic targets in colorectal cancer and provide new insights into the role of RNA metabolism in colorectal cancer progression and tumour immune regulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.